Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Oramed Pharmaceuticals Inc. (ORMP) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Oramed Pharmaceuticals Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1176309.
Total stock buying since 2014: $1,868,290.
Total stock sales since 2014: $8,046,360.
Total stock option exercises since 2014: $1,197,103.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 222,427 | $454,134 | 166,625 | $1,050,599 | 0 | $0 |
| 2022 | 0 | $0 | 10,000 | $94,100 | 26,667 | $113,601 |
| 2021 | 0 | $0 | 244,100 | $4,942,725 | 79,136 | $454,478 |
| 2019 | 80,837 | $273,903 | 0 | $0 | 0 | $0 |
| 2018 | 2,622 | $12,972 | 61 | $364 | 0 | $0 |
| 2017 | 142,450 | $1,096,218 | 142,450 | $1,096,218 | 152,771 | $627,311 |
| 2016 | 1,000 | $6,978 | 8,500 | $54,842 | 0 | $0 |
| 2015 | 3,200 | $14,087 | 52,000 | $462,729 | 0 | $0 |
| 2014 | 2,252 | $9,998 | 40,000 | $344,783 | 142,814 | $1,713 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-04 | 26,427 | $58,551 | 0 | $0 | 0 | $0 |
| 2023-03 | 196,000 | $395,583 | 100,000 | $200,999 | 0 | $0 |
| 2023-01 | 0 | $0 | 66,625 | $849,600 | 0 | $0 |
| 2022-08 | 0 | $0 | 0 | $0 | 20,000 | $81,600 |
| 2022-03 | 0 | $0 | 10,000 | $94,100 | 0 | $0 |
| 2022-02 | 0 | $0 | 0 | $0 | 6,667 | $32,001 |
| 2021-11 | 0 | $0 | 3,000 | $76,800 | 0 | $0 |
| 2021-09 | 0 | $0 | 21,100 | $442,825 | 0 | $0 |
| 2021-08 | 0 | $0 | 220,000 | $4,423,100 | 79,136 | $454,478 |
| 2019-09 | 25,000 | $73,125 | 0 | $0 | 0 | $0 |
| 2019-07 | 55,837 | $200,778 | 0 | $0 | 0 | $0 |
| 2018-08 | 2,500 | $12,250 | 0 | $0 | 0 | $0 |
| 2018-07 | 122 | $722 | 61 | $364 | 0 | $0 |
| 2017-10 | 0 | $0 | 0 | $0 | 28,896 | $135,639 |
| 2017-08 | 89,636 | $761,906 | 89,636 | $761,906 | 123,875 | $491,672 |
| 2017-04 | 52,814 | $334,312 | 52,814 | $334,312 | 0 | $0 |
| 2016-05 | 1,000 | $6,978 | 0 | $0 | 0 | $0 |
| 2016-03 | 0 | $0 | 8,500 | $54,842 | 0 | $0 |
| 2015-12 | 0 | $0 | 52,000 | $462,729 | 0 | $0 |
| 2015-05 | 600 | $3,966 | 0 | $0 | 0 | $0 |
| 2015-03 | 2,600 | $10,121 | 0 | $0 | 0 | $0 |
| 2014-09 | 0 | $0 | 40,000 | $344,783 | 0 | $0 |
| 2014-08 | 0 | $0 | 0 | $0 | 142,814 | $1,713 |
| 2014-06 | 2,252 | $9,998 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-04-04 | Mayer Arie (Director) | Buy | 7,600 | 2.21 | 16,796 |
| 2023-04-03 | Mayer Arie (Director) | Buy | 10,018 | 2.22 | 22,238 |
| 2023-03-16 | Kidron Nadav (President and CEO) | Buy | 26,000 | 2.04 | 53,014 |
| 2023-03-14 | Rozov Yadin (Director) | Buy | 50,000 | 2.05 | 102,450 |
| 2023-03-14 | Kidron Miriam (Chief Scientific Officer) | Sale | 100,000 | 2.01 | 200,999 |
| 2023-03-14 | Kidron Nadav (President and CEO) | Buy | 100,000 | 2.01 | 200,999 |
| 2023-03-13 | Rozov Yadin (Director) | Buy | 20,000 | 1.96 | 39,120 |
| 2023-01-03 | Rabinowitz Michael (Chief Commercial Officer) | Sale | 39,975 | 12.75 | 509,760 |
| 2022-08-08 | Sank Leonard (Director) | Option Ex | 20,000 | 4.08 | 81,600 |
| 2022-03-21 | Rakin Kevin | Sale | 10,000 | 9.41 | 94,100 |
| 2022-02-17 | Rakin Kevin | Option Ex | 6,667 | 4.80 | 32,001 |
| 2021-11-01 | Mayer Arie | Sale | 3,000 | 25.60 | 76,800 |
| 2021-09-16 | Rakin Kevin | Sale | 21,100 | 20.99 | 442,825 |
| 2021-08-09 | Kidron Nadav (President and CEO) | Sale | 220,000 | 20.11 | 4,423,100 |
| 2021-08-09 | Rakin Kevin | Option Ex | 79,136 | 5.74 | 454,478 |
| 2019-09-09 | Sank Leonard | Buy | 25,000 | 2.92 | 73,125 |
| 2019-07-18 | Sank Leonard | Buy | 4,497 | 3.85 | 17,335 |
| 2019-07-17 | Sank Leonard | Buy | 30,020 | 3.66 | 109,873 |
| 2019-07-16 | Sank Leonard | Buy | 20,000 | 3.47 | 69,320 |
| 2019-07-11 | Sank Leonard | Buy | 1,320 | 3.22 | 4,250 |
| 2018-08-09 | Friedman Aviad | Buy | 2,500 | 4.90 | 12,250 |
| 2018-07-11 | Kidron Nadav (President and CEO) | Buy | 122 | 5.92 | 722 |
| 2018-07-10 | Kidron Nadav (President and CEO) | Sale | 61 | 5.98 | 364 |
| 2017-10-31 | Slager David Mark | Option Ex | 16,892 | 3.77 | 63,615 |
| 2017-10-23 | Sank Leonard | Option Ex | 12,004 | 6.00 | 72,024 |
| 2017-08-17 | Slager David Mark | Option Ex | 112,613 | 3.77 | 424,100 |
| 2017-08-15 | Sank Leonard | Option Ex | 11,262 | 6.00 | 67,572 |
| 2017-08-02 | Li Xiaopeng | Buy | 89,636 | 8.50 | 761,906 |
| 2017-08-02 | Kidron Miriam (Chief Scientific Officer) | Sale | 89,636 | 8.50 | 761,906 |
| 2017-04-19 | Li Xiaopeng | Buy | 52,814 | 6.33 | 334,312 |
| 2017-04-19 | Kidron Miriam (Chief Scientific Officer) | Sale | 52,814 | 6.33 | 334,312 |
| 2016-05-12 | Kidron Nadav (President and CEO) | Buy | 1,000 | 6.98 | 6,978 |
| 2016-03-10 | Jacob Harold | Sale | 8,500 | 6.45 | 54,842 |
| 2015-12-30 | Kidron Miriam (Chief Technology Officer) | Sale | 24,000 | 8.61 | 206,712 |
| 2015-12-29 | Kidron Miriam (Chief Technology Officer) | Sale | 15,000 | 9.08 | 136,185 |
| 2015-12-28 | Kidron Miriam (Chief Technology Officer) | Sale | 11,000 | 9.27 | 101,915 |
| 2015-12-09 | Berelowitz Michael | Sale | 700 | 9.44 | 6,608 |
| 2015-12-08 | Berelowitz Michael | Sale | 761 | 8.70 | 6,620 |
| 2015-12-07 | Berelowitz Michael | Sale | 539 | 8.70 | 4,689 |
| 2015-05-12 | Kidron Nadav (President and CEO) | Buy | 600 | 6.61 | 3,966 |
| 2015-03-19 | Kidron Nadav (President and CEO) | Buy | 1,600 | 3.96 | 6,331 |
| 2015-03-18 | Kidron Nadav (President and CEO) | Buy | 1,000 | 3.79 | 3,790 |
| 2014-09-11 | Kidron Miriam (Chief Technology Officer) | Sale | 8,699 | 8.44 | 73,402 |
| 2014-09-10 | Kidron Miriam (Chief Technology Officer) | Sale | 23,000 | 8.40 | 193,269 |
| 2014-09-04 | Kidron Miriam (Chief Technology Officer) | Sale | 8,301 | 9.41 | 78,112 |
| 2014-08-01 | Kidron Miriam (Chief Technology Officer) | Option Ex | 142,814 | .01 | 1,713 |
| 2014-06-06 | Slager David Mark | Buy | 2,252 | 4.44 | 9,998 |
Insider trading activities including stock purchases, stock sales, and option exercises of ORMP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Oramed Pharmaceuticals Inc. (symbol ORMP, CIK number 1176309) see the Securities and Exchange Commission (SEC) website.